Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form
• People aged between 18 and 75 years old at the time of signing the consent form
• People with a general health and activity level rated as reasonably functional (scored 0–2 on a standard oncology scale), and who are expected to live for more than 3 months
• People who have been confirmed through a tissue biopsy to have one of the following types of B-cell lymphoma, diagnosed using 2022 World Health Organization criteria: a slow-growing (indolent) B-cell lymphoma that has come back or stopped responding to treatment, or Diffuse Large B-Cell Lymphoma (DLBCL)
• People with relapsed or treatment-resistant slow-growing B-cell lymphoma who have already received at least one previous course of standard treatment
• People who have at least one area of lymphoma that can be measured on scans
• People whose major organs (such as heart, liver, and kidneys) are functioning adequately
• Women of childbearing age who agree to use contraception during the study and for 6 months after it ends, have a negative pregnancy test within 7 days before joining, and are not breastfeeding; men who agree to use contraception during the study and for 6 months after it ends

Who may not be able to join:

• People who have had, or currently have, another type of cancer within the past 3 years
• People with known or suspected spread of lymphoma to the brain or spinal cord (central nervous system)
• People with relapsed or treatment-resistant slow-growing B-cell lymphoma who have previously received a stem cell transplant using a donor's cells, or who received their own stem cell transplant within the 3 months before starting treatment
• People with relapsed or treatment-resistant slow-growing B-cell lymphoma who still have significant side effects from previous treatments (above a mild level), not including hair loss or fatigue
• People who have difficulty absorbing oral (swallowed) medications, such as those who cannot swallow, have ongoing diarrhoea, or have a bowel blockage
• People who have had major surgery or a serious injury within 28 days before the study treatment starts
• People who have experienced a serious blood clot or related event within 6 months before starting treatment
• People with a history of substance abuse involving mind-altering drugs that has not been resolved, or people with a diagnosed mental health disorder
• People with any serious or uncontrolled medical condition
• People who have received a live vaccine or mRNA vaccine within 4 weeks before the first dose, or who plan to receive one during the study
• People who have taken part in another cancer drug clinical trial within 4 weeks before the first dose
• People who, in the opinion of the study doctor, have other conditions that could put them at risk or make it difficult to complete the study

Important: Always verify eligibility with the trial site directly before applying.